Pacer Advisors Inc. Has $3.70 Million Position in Celgene Corporation (CELG)
Pacer Advisors Inc. boosted its position in Celgene Corporation (NASDAQ:CELG) by 12.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,466 shares of the biopharmaceutical company’s stock after purchasing an additional 3,239 shares during the quarter. Pacer Advisors Inc.’s holdings in Celgene Corporation were worth $3,697,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Neuberger Berman Group LLC raised its stake in Celgene Corporation by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC acquired a new position in Celgene Corporation in the 2nd quarter valued at about $3,616,000. Lincoln Capital Corp raised its stake in Celgene Corporation by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares during the last quarter. Swiss National Bank raised its stake in Celgene Corporation by 27.2% in the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after purchasing an additional 588,000 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Celgene Corporation by 9.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after purchasing an additional 54,210 shares during the last quarter. 79.39% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $166.00 target price (up previously from $163.00) on shares of Celgene Corporation in a research note on Monday. Cantor Fitzgerald reissued a “hold” rating and issued a $112.00 target price on shares of Celgene Corporation in a research note on Monday. J P Morgan Chase & Co set a $123.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Friday. UBS AG dropped their price objective on shares of Celgene Corporation from $146.00 to $120.00 and set a “buy” rating for the company in a research note on Friday. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $140.00 price objective (down previously from $154.00) on shares of Celgene Corporation in a research note on Friday. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $139.64.
WARNING: This article was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/10/31/pacer-advisors-inc-has-3-70-million-position-in-celgene-corporation-celg.html.
Celgene Corporation (NASDAQ CELG) opened at 100.97 on Tuesday. The company’s 50-day moving average price is $135.78 and its 200 day moving average price is $129.85. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a market capitalization of $78.99 billion, a PE ratio of 31.27 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the firm earned $1.58 EPS. Celgene Corporation’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.
In other news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 46,233 shares of company stock worth $6,268,259 in the last three months. 0.95% of the stock is owned by insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.